A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
June 15, 2017
End Date
June 20, 2020
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
June 15, 2017
End Date
June 20, 2020